Scientific Advisory Board
MBC Pharma, Inc.
Dr. Janjic is the Chief Scientific Officer at SomaLogic, Inc. Prior to joining SomaLogic, Dr. Janjic was the CSO at Replidyne, Inc. in Louisville, Colorado, a biotechnology company focusing on the development of new small-molecule antibacterial agents.Prior to joining Replidyne, Dr. Janjic was Senior Director, Drug Discovery, at NeXstar Pharmaceuticals in Boulder, Colorado. Dr. Janjic joined NeXstar in its formative stages and participated in its development to a publicly-traded biotechnology company valued in excess of $500 million. At NeXstar, Dr. Janjic was responsible for creating a pipeline of aptamer-based drug candidates for pre-clinical and clinical development. His contributions included the discovery and early development of Macugen, the first-in-class FDA-approved treatment for macular degeneration and named Innovative Pharmaceutical Product of the Year in 2005. Dr. Janjic's duties also included technology transfer to major corporate partners and linking of discovery research efforts with business development activities. Dr. Janjic is an author of 30 original research papers and an inventor on 10 issued patents. Dr. Janjic received his B.S. degree in Molecular Biology and Ph.D. in Physical Organic Chemistry from the University of Washington in Seattle and completed his postdoctoral training at the Scripps Research Institute in La Jolla as a Cancer Research Institute Fellow.